eyewire

Moorfields Private Launches Eye Health Assessment Service for Patients Taking GLP-1 Medications

Key Takeaways Moorfields Private has introduced specialist eye assessments for patients taking GLP-1 medications, including ...
eyewire

AAO Posters Explore Cryopreserved Amniotic Membrane in Complex Ocular Surface Disease

Key Takeaways Two AAO case reports examine cryopreserved amniotic membrane in neurotrophic keratitis and severe HSV keratitis ...
eyewire

European Commission Approves Roche’s Susvimo for Wet AMD

Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry ...
eyewire

MyEyeDr. to Acquire EyeCare Partners Optometry Division, Adding More than 300 Offices

MyEyeDr. has agreed to acquire EyeCare Partners' optometry division, including more than 300 offices across 5 eye care brands MyEyeDr. said the expanded organization will support greater access to ...
eyewire

Technology Behind Robotic Cataract Surgery

Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements.
eyewire

Kodiak Reports Phase 3 DAYBREAK Trial Meets Primary Endpoints for Zenkuda in Wet AMD

Both Zenkuda and tabirafusp-ted met the phase 3 DAYBREAK primary endpoints, achieving noninferiority to aflibercept for vision gains at 1 year in patients with wet AMD Kodiak reported that 54% of ...
eyewire

Expanding Access to Cataract Surgery Globally

B+L Advances Two Ophthalmic Pipeline Therapies in DED and Ocular Surface Pain ...
eyewire

Experience for Patients and Surgeons

Merck's Remigromig Meets Primary Endpoint in Phase 2b/3 BRUNELLO Trial for DME ...
eyewire

Merck's Remigromig Meets Primary Endpoint in Phase 2b/3 BRUNELLO Trial for DME

Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry ...
eyewire

Kodiak Reports Phase 3 Trial Meets Primary Endpoints for Zenkuda in Wet AMD

Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry ...
eyewire

EssilorLuxottica Reports 6-Month Clinical Trial Results for Stellest 2.0 Lenses

Stellest 2.0 lenses showed 6-month treatment effects of 0.51 D for myopia progression and 0.21 mm for axial elongation versus single-vision lenses in an ongoing trial in China More than 90% of ...